BTIG Maintains Buy on DermTech, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Mark Massaro maintains a Buy rating on DermTech (NASDAQ:DMTK) but lowers the price target from $4 to $2.

March 07, 2024 | 4:42 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BTIG analyst Mark Massaro maintains a Buy rating on DermTech but lowers the price target from $4 to $2.
While the maintenance of a Buy rating indicates continued confidence in DermTech's fundamentals and potential growth, the reduction in the price target suggests a reassessment of the short-term price expectations, possibly due to market conditions or company-specific factors not detailed in the article. This mixed signal could lead to short-term uncertainty among investors.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100